» Articles » PMID: 21429186

Characterization of the Human Endogenous Retrovirus K Gag Protein: Identification of Protease Cleavage Sites

Overview
Journal Retrovirology
Publisher Biomed Central
Specialty Microbiology
Date 2011 Mar 25
PMID 21429186
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Viral genomes of the human endogenous retrovirus K (HERV-K) family are integrated into the human chromosome and are transmitted vertically as Mendelian genes. Although viral particles are released by some transformed cells, they have never been shown to be infectious. In general, gammaretroviruses are produced as immature viral particles by accumulation of the Gag polyproteins at the plasma membrane, which subsequently bud from the cell surface. After release from the cell, Gag is further processed by proteolytic cleavage by the viral protease (PR), which results in morphologically mature particles with condensed cores. The HERV-K Gag polyprotein processing and function has not yet been precisely determined.

Results: We generated a recombinant poxvirus, encoding the human endogenous retrovirus K consensus gag-pro-pol genes (MVA-HERV-Kcon) and obtained high levels of HERV-K Gag expression. The resulting retroviral particle assembled at the plasma membrane, as is typical for gammaretroviruses; and immature as well as mature retrovirus-like particles (VLPs) were observed around the infected cells. VLPs were purified, concentrated and separated by two-dimensional gel electrophoresis. The HERV-K Gag fragments were identified by mass spectroscopy and N-terminal sequencing which revealed that HERV-K Gag is processed into MA, a short spacer peptide, p15, CA and NC.

Conclusion: The cleavage sites of HERV-K Gag were mapped and found to be highly conserved among HERV-K genomes. The consensus HERV-K gag gene used in this study is known to support viral, infectivity 1, and thus the cleavage sites that were mapped in this study for all the Gag components are relevant for HERV-K infectivity.

Citing Articles

Molecular architecture and conservation of an immature human endogenous retrovirus.

Krebs A, Liu H, Zhou Y, Rey J, Levintov L, Shen J Nat Commun. 2023; 14(1):5149.

PMID: 37620323 PMC: 10449913. DOI: 10.1038/s41467-023-40786-w.


Molecular architecture and conservation of an immature human endogenous retrovirus.

Krebs A, Liu H, Zhou Y, Rey J, Levintov L, Shen J bioRxiv. 2023; .

PMID: 37333227 PMC: 10274761. DOI: 10.1101/2023.06.07.544027.


Human Endogenous Retrovirus, SARS-CoV-2, and HIV Promote PAH via Inflammation and Growth Stimulation.

Wang D, Gomes M, Mo Y, Prohaska C, Zhang L, Chelvanambi S Int J Mol Sci. 2023; 24(8).

PMID: 37108634 PMC: 10138839. DOI: 10.3390/ijms24087472.


Screening and Identification of Human Endogenous Retrovirus-K mRNAs for Breast Cancer Through Integrative Analysis of Multiple Datasets.

Wei Y, Wei H, Wei Y, Tan A, Chen X, Liao X Front Oncol. 2022; 12:820883.

PMID: 35265522 PMC: 8900282. DOI: 10.3389/fonc.2022.820883.


A Comprehensive Analysis of Human Endogenous Retroviruses HERV-K (HML.2) from Teratocarcinoma Cell Lines and Detection of Viral Cargo in Microvesicles.

Morozov V, Morozov A Int J Mol Sci. 2021; 22(22).

PMID: 34830279 PMC: 8619701. DOI: 10.3390/ijms222212398.


References
1.
Enserink M . Chronic fatigue syndrome. New XMRV paper looks good, skeptics admit--yet doubts linger. Science. 2010; 329(5995):1000. DOI: 10.1126/science.329.5995.1000. View

2.
Dewannieux M, Harper F, Richaud A, Letzelter C, Ribet D, Pierron G . Identification of an infectious progenitor for the multiple-copy HERV-K human endogenous retroelements. Genome Res. 2006; 16(12):1548-56. PMC: 1665638. DOI: 10.1101/gr.5565706. View

3.
Vogt V . Proteolytic processing and particle maturation. Curr Top Microbiol Immunol. 1996; 214:95-131. DOI: 10.1007/978-3-642-80145-7_4. View

4.
Martin-Serrano J . The role of ubiquitin in retroviral egress. Traffic. 2007; 8(10):1297-303. DOI: 10.1111/j.1600-0854.2007.00609.x. View

5.
Staib C, Lowel M, Erfle V, Sutter G . Improved host range selection for recombinant modified vaccinia virus Ankara. Biotechniques. 2003; 34(4):694-6, 698, 700. DOI: 10.2144/03344bm02. View